Publication: Increased expression of matrix metalloproteinase-2 -MMP-2- predicts tumour recurrence and unfavourable outcome in non-small cell lung cancer
Loading...
Date
2008
Authors
Leinonen, Tero ; Pirinen, Risto ; Böhm, Jan ; Johansson, Risto ; Kosma, Veli-Matti
item.page.secondaryauthor
item.page.director
Publisher
Murcia : F. Hernández
publication.page.editor
publication.page.department
DOI
item.page.type
info:eu-repo/semantics/article
Description
Abstract
The purpose of this study was to analyse the
expression of matrix metalloproteinase-2 (MMP-2) and
its extracellular matrix metalloproteinase inducer
(EMMPRIN) in non-small cell lung cancer (NSCLC),
and to evaluate their significance to predict tumour
behaviour.
The study consists of 212 patients treated by the
resection of the tumour. Tumour samples were stained
immunohistochemically, and the expression of MMP-2
and EMMPRIN was evaluated both in tumour cells and
in peritumoural stromal tissue. The results were
compared with clinicopathological factors and survival
of the patients.
High expression of MMP-2 in tumour cells was
found in 83 out of 191 cases (44%). Adenocarcinomas
showed more often high expression of MMP-2 as
compared with squamous cell or large cell carcinomas
(p=0.001). High cancer cell associated MMP-2
expression was associated with increased tumour
recurrence (p=0.001). Tumour stroma showed positive
staining in 162 (98%) cases and was considered highly
stained in 120 (72%) cases. The high stromal MMP-2
expression was noticed more often among large cell
carcinomas as compared with other histological types (p=0.007). High cancer cell associated EMMPRIN
expression was found in 115 (61%) cases and was
associated only with high MMP-2 expression in tumour
cells (p=0.006).
In overall survival (OS) and disease free survival
(DFS) analyses, type of tumour (p=0.001 and p=0.0004),
advanced stage (p=0.001 and p=0.013) and high MMP-2
expression in tumour cells (p=0.018 and p=0.001) were
associated with poor survival. Also, high stromal MMP-2 expression was related to poor outcome in both OS and
DFS analyses (p=0.010 and 0.045, respectively). In
multivariate analysis, stromal MMP-2 expression
retained its prognostic value to predict OS and DFS
(p=0.028 and p=0.039, respectively), together with
tumour type and stage (p=0.017, p=0.001 and p=0.021,
p=0.008, respectively).
The present study shows the significant prognostic
value of MMP-2 in NSCLC suggesting that the use of
MMP-2 is valuable in determining the patients with
more aggressive disease.
publication.page.subject
Citation
item.page.embargo
Ir a Estadísticas
Sin licencia Creative Commons.